Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 4, 2009, Pages 541-548

  Han, Young Sang ^a,b   Lee, Ji Eun ^a,b   Jung, Ji Won ^a   Lee, Jong Soo ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

Author keywords

Angiogenesis; Bevacizumab; Corneal neovascularization; Human umbilical vein endothelial cells

Indexed keywords

BEVACIZUMAB; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOMICROSCOPY; CELL ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA FLUORESCEIN ANGIOGRAPHY; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62149145802     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0976-3     Document Type: Article

References (20)

1. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354, doi: 10.1097/00006982-200603000-00016
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, doi: 10.1016/ j.ophtha.2005.11.019
3. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-7848, doi: 10.1158/0008-5472.CAN-06-1010
4. Barros LF, Belfort-Jr R (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389-394, doi: 10.1590/S0001-37652007000300004
5. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1-9, doi: 10.1016/j.ajo.2006.02.037
6. Beck L Jr, D'Amore PA (1997) Vascular development: Cellular and molecular regulation. FASEB J 11:365-373
7. BenEzra D, Hemo I, Maftzir G (1990) In vivo angiogenic activity of interleukins. Arch Ophthalmol 108:573-576
8. Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19:526-533, doi: 10.1097/ 00003226-200007000-00025
9. DeStafeno JJ, Kim T (2007) Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125:834-836, doi: 10.1001/ archopht.125.6.834
10. Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577-1579, doi: 10.1007/s00417-007-0587-4
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, doi: 10.1056/NEJMoa032691
12. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, Lee SH, Kim MS, Lee HW, Shin WS, Park IC, Rhee CH, Hong SI (2006) Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 118:2711-2720, doi: 10.1002/ ijc.21641
13. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804-807, doi: 10.1136/bjo.2006.107912
14. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047, doi: 10.1016/ j.ophtha.2005.02.007
15. Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU (2007) Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 91:827-831, doi: 10.1136/ bjo.2006.109702
16. Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514-2522
17. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-339
18. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278, doi: 10.1097/00006982-200603000-00004
19. Sunderkötter C, Roth J, Sorg C (1990) Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am J Pathol 137:511-515
20. Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335-345, doi: 10.1007/s10456-004-8272-2